CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018
Published: Apr 17, 2018
- CBT-102 demonstrated tumor regression in fifty-two patient derived xenograft models, including non-small cell lung, colorectal, gastric, and hepatocellular carcinoma.
- No significant influence on the action potential of rabbit heart Purkinje fibers as well as QT and QTc in Beagle dogs across a dose range of 15–67.5 mg/kg compared to sorafenib.
- CBT-102 demonstrated superior efficacy in LIMsh050 and PLCPRF5 human hepatocellular carcinoma animal models compared to sorafenib and does not appear to have the cardiac liability observed with sorafenib.
“We are highly encouraged by the preclinical safety and efficacy data of CBT-102,” said Sanjeev Redkar, Ph.D., President and Chief Executive Officer. “Based on this data set, we plan to advance CBT-102 into GLP toxicology studies in 2018 with an aim to enter the clinic in early 2019 in combination with other agents in our portfolio.”
About CBT Pharmaceuticals, Inc.
CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to tame cancer. The company’s existing pipeline of five development-stage assets include three novel humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and two targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.cbtpharma.com and follow us on Twitter @CBTpharma.
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
Source: CBT Pharmaceuticals, Inc.